A Search Service for Abbreviation / Long Form

■ Abbreviation / Long Form : ETA / etanercept

[Related PubMed/MEDLINE]
Total Number of Papers: 72
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   ETA  (>> Co-occurring Abbreviation)
Long Form:   etanercept
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 Comparative analysis of the etanercept efficacy in children with juvenile idiopathic arthritis under the age of 4 years and children of older age groups using the propensity score matching method. ACR, IQR, JIA, JNR, PSM, RAO, RDD
2019 Does a mandatory non-medical switch from originator to biosimilar etanercept lead to increase in healthcare use and costs? A Danish register-based study of patients with inflammatory arthritis. GEE
2019 Dynamics of concomitant therapy in children with juvenile idiopathic arthritis treated with etanercept and methotrexate. JIA, MTX, orGCs
2019 Effects of etanercept, a tumor necrosis factor receptor fusion protein, on primary cell cultures prepared from intact human intervertebral disc tissue. NP, TNF
2019 Efficacy and survival of biologic agents in psoriasis: a practical real-life 12-year experience in a French dermatology department. ADA, UST
2019 ETA-mediated anti-TNF-alpha therapy ameliorates the phenotype of PCOS model induced by letrozole. LET, PCOS, TNF
2019 Polarization of Rheumatoid Macrophages by TNF Targeting Through an IL-10/STAT3 Mechanism. ADA, bDMARDs, RA, RTX, TCZ
2019 Synovial inflammation analyzed by 3-T magnetic resonance imaging in etanercept-treated patients with rheumatoid arthritis indicates persistent disease activity despite of clinical remission: A pilot study. cDMARDs, DAS28, RA, RAMRIS, TNFi
2019 Use of anti-inflammatory agents in clinical islet cell transplants: A qualitative systematic analysis. TNF
10  2019 [Etanercept in routine German clinical practice to treat rheumatoid arthritis patients : Aone-year observational study on effectiveness, safety and health economics]. DAS, FFbH, LOCF, RA, VAS
11  2018 Additional effect of etanercept or infliximab on the liver function tests of patients with rheumatoid arthritis: a cohort study. AST, bDMARDs, cDMARDs, DMARDs, INF, MTX, RA
12  2018 Correlation between HLA haplotypes and the development of antidrug antibodies in a cohort of patients with rheumatic diseases. ADA, ADAs, AS, CERT, GOL, HLA, IFX, PsA, RA
13  2018 Etanercept Prevents Histopathological Damage after Spinal Cord Injury in Rats. CAT, IL-1beta, SCI, SOD, TNF-alpha
14  2018 Persistency of Biologic Therapies for Plaque Psoriasis in 2 Large Community Practices. ADA, IFX, UST
15  2018 Therapeutic Evaluation of Tumor Necrosis Factor-alpha Antagonist Etanercept against Traumatic Brain Injury in Rats: Ultrastructural, Pathological, and Biochemical Analyses. i.p, TBI
16  2018 TNFalpha expressed on the surface of microparticles modulates endothelial cell fate in rheumatoid arthritis. HC, MPs, RA, TNF-alpha
17  2017 Adherence and dosing interval of subcutaneous antitumour necrosis factor biologics among patients with inflammatory arthritis: analysis from a Canadian administrative database. ADA, CZP, GLM, SC-TNFis
18  2017 Combination therapy with vedolizumab and etanercept in a patient with pouchitis and spondylarthritis. SpA, VDZ
19  2017 Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry. ACR, AEs, IL-1i, JADAS10, RR, sJIA, TOC
20  2017 Inflammation Is an Important Covariate for the Crosstalk of Sleep and the HPA Axis in Rheumatoid Arthritis. ACTH, CRP, HPA, MTX, PSG, RA
21  2017 Second-line treatment persistence and costs among patients with immune-mediated rheumatic diseases treated with subcutaneous TNF-alpha inhibitors. ADA, CZP, GLM, IMRDs, PSM, SC-TNFis
22  2016 "Drug-Survival"-Raten und Grunde fur den Abbruch von Systemtherapien bei Psoriasis. ACI, ADA, CyA, HR, INF, MTX, UST
23  2016 Characterizing patients with psoriasis on injectable biologics adalimumab, etanercept, and ustekinumab: A chart review study. ADA, PsO, UST
24  2016 Drug survival rates and reasons for drug discontinuation in psoriasis. ACI, ADA, CyA, FAE, HR, INF, MTX, UST
25  2016 Effects of treatment with etanercept versus methotrexate on sleep quality, fatigue and selected immune parameters in patients with active rheumatoid arthritis. BL, CRP, HAQ-DI, MTX
26  2016 Efficacy of etanercept for treating the active rheumatoid arthritis: an updated meta-analysis. CIs, MTX, RA, RRs
27  2016 Evaluation of the immunogenicity of the 13-valent conjugated pneumococcal vaccine in rheumatoid arthritis patients treated with etanercept. MTX, pAR, RA
28  2016 Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA). ADA, ESI, EY, IBD, JIA, MTX, pJIA, SAE
29  2016 Off-label Use of Tocilizumab in Psoriatic Arthritis: Case Series and Review of the Literature. ADA, PsA, TCZ
30  2016 Safety and efficacy of etanercept and adalimumab in children aged 2 to 4years with juvenile idiopathic arthritis. ADA, JIA, MDA
31  2016 Treatment persistence among patients with immune-mediated rheumatic disease newly treated with subcutaneous TNF-alpha inhibitors and costs associated with non-persistence. ADA, CZP, GLM, HCRU, IMRD, SC-TNFi
32  2015 Drug survival and causes of discontinuation of the first anti-TNF in ankylosing spondylitis compared with rheumatoid arthritis: analysis from BIOBADABRASIL. ADA, anti-TNF, AS, CI, IFX, RA
33  2015 Influence of Immunogenicity on the Efficacy of Long-Term Treatment with TNF alpha Blockers in Rheumatoid Arthritis and Spondyloarthritis Patients. ADA, INF, RA, SpA
34  2015 Medication adherence and attrition to biologic treatment in rheumatoid arthritis patients. ADA, OR, PDC, RA
35  2015 Switching from an anti-TNF monoclonal antibody to soluble TNF-receptor yields better results than vice versa: An observational retrospective study of 72rheumatoid arthritis switchers. ADA, IFX, RA, TNFi
36  2015 The efficiency of biologic therapy in a group of patients with rheumatoid arthritis. ADA, anti-TNF, CRP, ESR, IFX, RA, RTX
37  2015 [Biological treatment in severe Still's disease--a case report]. anti-TNF-alpha, CER, DMARDs, JIA, MTX
38  2014 Body weight, gender and response to TNF-alpha blockers in axial spondyloarthritis. IFX, OR
39  2014 Current evidence of anti-tumor necrosis factor alpha treatment efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach of individual drugs. ACU, ADA, anti-TNFalpha, DMARDs, EBM, INF
40  2014 Drug retention rates and treatment discontinuation among anti-TNF-alpha agents in psoriatic arthritis and ankylosing spondylitis in clinical practice. ADA, ANOVA, AS, DMARDs, INF, PsA
41  2014 Etanercept reduces thermal and mechanical orofacial hyperalgesia following inflammation and neuropathic injury. CION, TNF-alpha
42  2014 Good correlation between changes in objective and subjective signs of inflammation in patients with short- but not long duration of axial spondyloarthritis treated with tumor necrosis factor-blockers. ADA, ASDAS, BASDAI, BASFI, CI, CRP, MRI, PRO, SIJ, SpA, Trial 1
43  2014 Predictive factors for partial remission according to the Ankylosing Spondylitis Assessment Study working group in patients with ankylosing spondylitis treated with anti-TNFalpha drugs. ADA, AS, BASDAI, BASFI, BASMI, CRP, ESR, INF, PR
44  2014 The impact of conventional DMARD and biological therapies on CD4+ cell subsets in rheumatoid arthritis: a follow-up study. ADA, DMARD, GCS, IFX, MTX, RA
45  2013 Remission in ankylosing spondylitis treated with anti-TNF-alpha drugs: a national multicentre study. ADA, INF, PR
46  2013 Rituximab versus anti-TNF in patients who previously failed one TNF inhibitor in an observational cohort. EULAR, mAb, RTX, STURE, TNF
47  2013 Similar response rates in patients with ankylosing spondylitis and non-radiographic axial spondyloarthritis after 1 year of treatment with etanercept: results from the ESTHER trial. AS, BASDAI, nr-axSpA, SI joints
48  2013 The combination of valacyclovir with an anti-TNF alpha antibody increases survival rate compared to antiviral therapy alone in a murine model of herpes simplex virus encephalitis. HSV-1, TNF-alpha, VACV
49  2013 Therapeutic potential of tumour necrosis factor-alpha antagonists in patients with chronic heart failure. CHF, INF, RA, TNF-alpha
50  2012 Anti TNF-alpha in refractory Takayasu's arteritis: cases series and review of the literature. IFX, TA, TNF-alpha
51  2012 Cost-effectiveness modelling of sequential biologic strategies for the treatment of moderate to severe rheumatoid arthritis in Finland. ABA, ADA, INF, LDAS, MHDAS, RA, RS, RTX
52  2012 Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. ASAS
53  2012 Long-term outcome of patients with JIA treated with etanercept, results of the biologic register JuMBO. HRQoL
54  2011 Comparison of aromatase inhibitor (letrozole) and immunomodulators (infliximab and etanercept) on the regression of endometriotic implants in a rat model. INF
55  2011 Cost-effectiveness of etanercept treatment in early active rheumatoid arthritis followed by dose adjustment. MTX, QALY, RA
56  2011 Number and phenotype of rheumatoid arthritis patients' CD4+CD25hi regulatory T cells are not affected by adalimumab or etanercept. ADA
57  2011 Relationship between active inflammatory lesions in the spine and sacroiliac joints and new development of chronic lesions on whole-body MRI in early axial spondyloarthritis: results of the ESTHER trial at week 48. SI joints, SpA, SSZ, VUs, WB-MRI
58  2010 Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR). ADA, anti-TNF, INF, RA, TB
59  2010 Minimal influence of tocilizumab on IFN-gamma synthesis by tuberculosis antigens. anti-TB, IFN-gamma, IL, INF, Mtb, TCZ, TNF
60  2010 Switching from infliximab or etanercept to adalimumab in resistant or intolerant patients with spondyloarthritis: a 4-year study. ADA, INF
61  2010 The formation of autoantibodies and antibodies to TNF-alpha blocking agents in relation to clinical response in patients with ankylosing spondylitis. ADA, IFX
62  2009 A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis. ACR, RR
63  2009 Effects of etanercept on sodium taurocholate-induced acute pancreatitis in rats. MDA, MPO
64  2009 Trends in RA patients' adherence to subcutaneous anti-TNF therapies and costs. ADA, HR, PH, RA
65  2008 Acid sphingomyelinase involvement in tumor necrosis factor alpha-regulated vascular and steroid disruption during luteolysis in vivo. CL, MVECs, PGF
66  2008 Anti-tumour necrosis factor therapy in patients with refractory Takayasu arteritis: long-term follow-up. IFX, TAK, TNF
67  2007 [Monitoring of clinical course in TNF inhibitor treatment for rheumatoid arthritis--efficacy evaluation, adverse effect detection, and prediction of clinical response]. INF, RA, TNF
68  2006 Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. ADA, CFP, IFN, Ifx, Mtb, mTNF, PPD, TB, TNF
69  2006 Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register. BSR, DMARDs, EULAR, HAQ, INF, MTX, RA, TNF-alpha
70  2005 Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo-controlled study. AIED, PLA
71  2003 The effect of etanercept and infliximab on the production of tumour necrosis factor alpha, interferon-gamma and GM-CSF in in vivo activated intestinal T lymphocyte cultures. CD, GM-CSF, IFN-gamma, Ifx, RA, tmb-TNF-alpha
72  2001 Comparison of rheumatoid arthritis care costs in patients starting therapy with leflunomide versus etanercept. LEF, RA